Of the 111 KDDF support tasks selected by the government last year, 17 are confirmed to be immuno-cancer drugs. Kim Soon-nam, head of KDDF R&D, who is leading the project, predicted, "In the future, R&D tasks related to immuno-cancer drugs will increase further."

Kim Soon-nam, head of the headquarters, attended a session under the theme of "Trends in the Development of Immuno-cancer Drugs" at "2022 BIO Korea" held at COEX in Seoul on the 11th and introduced it as such. According to him, the government will invest a total of 2 trillion won for 10 years from 2021 to 2030 to develop KDDF. The goal of the project is to support a total of 1,234 projects over a decade and produce four new drugs approved by th